Position in APGE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$836,199
New position
Shares Held
6,300
first reported quarter
Ownership
0.008%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#188
of 285 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Penserra Capital Management LLC holds $16,002,475 across 25 Biotechnology names. APGE ranks #7 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
54,216 | $3,080,010 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
11,268 | $2,758,068 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
50,017 | $2,747,933 | |
| 4 | KRYS |
Krystal Biotech, Inc.
|
5,142 | $1,911,127 | |
| 5 | BCAX |
Bicara Therapeutics Inc.
|
31,066 | $922,349 | |
| 6 | ELVN |
Enliven Therapeutics, Inc.
|
16,660 | $845,495 | |
| 7 | APGE |
Apogee Therapeutics, Inc.
This page
|
6,300 | $836,199 | |
| 8 | RCUS |
Arcus Biosciences, Inc.
|
26,929 | $830,221 |
All Filings in APGE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $836,199 | 6,300 | Shares | Defined | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||